Skip to content
POM-V Prescription Required Companion Animal

Librela 20 mg solution for injection for dogs

Active ingredient: Bedinvetmab

Form

Injection

Species

Dogs

Manufacturer

Zoetis Belgium

VMD MA No.

EU/2/20/261/010-012

What it's used for

For the alleviation of pain associated with osteoarthritis in dogs.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bedinvetmab

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Librela 20 mg solution for injection for dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the alleviation of pain associated with osteoarthritis in dogs.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in dogs under 12 months.
Do not use in animals intended for breeding.
Do not use in pregnant or lactating animals.
Dogs:
Uncommon
(1 to 10 animals / 1,000
animals treated):
Injection site reaction (e.g. injection site swelling,
injection site warmth)
.
Rare
(1 to 10 animals / 10,000
animals treated):
Diarrhoea, Emesis.
Ataxia
.
Polyuria, Urinary incontinence.
Anorexia
, Lethargy, Polydipsia.
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Hypersensitivity reaction (anaphylaxis, facial
swelling, pruritus)
, Immune-mediated haemolytic
anaemia, Immune-mediated polyarthritis,
Immune-mediated thrombocytopenia.
Paresis, Paralysis, Seizure.
Mild
Including proprioceptive ataxia.
Often related to a transient reduced appetite.
In case of such reactions, appropriate symptomatic treatment should be
administered.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
This veterinary medicinal product may induce transient or persistent anti-drug
antibodies.
The induction of such antibodies is uncommon and may have no effect or may result
in a decrease in efficacy in animals that responded to treatment previously.
If no or limited response is observed within one month after initial dosing, an
improvement in response may be observed after administration of a second dose

Revised: January 2026
AN: 02281/2025
one month later. However, if the animal does not show a better response after the
second dose, the veterinary surgeon should consider alternative treatments.

i) Special precautions for use in animals
Where a dog has not been able to properly exercise prior to treatment due to its
clinical condition, it is recommended that the dog is gradually (over a few weeks)
allowed to increase the amount of exercise they take (to prevent overexercise by
some dogs).
Caution should be used when treating patients with the following pre-existing
conditions: immune-mediated haemolytic anaemia, immune-mediated polyarthritis,
immune-mediated thrombocytopenia.
Caution should be used when treating patients with pre-existing seizure disorder.
ii) Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case
of accidental self-injection. Repeated self-administration may increase the risk of
hypersensitivity reactions.
The importance of nerve growth factor (NGF) in ensuring normal foetal nervous
system development is well-established and laboratory studies conducted on non-
human primates with human anti-NGF antibodies have shown evidence of
reproductive and developmental toxicity. Pregnant women, women trying to conceive
and breastfeeding women should take extreme care to avoid accidental self-injection.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
iii) Other precautions
Not applicable.

Revised: January 2026
AN: 02281/2025
In a laboratory study over a 2-week period in young, healthy dogs without
osteoarthritis, this veterinary medicinal product had no adverse effect when

Revised: January 2026
AN: 02281/2025
concomitantly administered with a non-steroidal anti-inflammatory product
(carprofen).
There are no safety data on the concurrent long-term use of NSAIDs and
bedinvetmab in dogs.
In clinical trials in humans, rapidly progressive osteoarthritis has been reported in
patients receiving humanised anti-NGF monoclonal antibody therapy. The incidence
of these events increased with high doses and in those human patients that received
long-term (more than 90 days) non-steroidal anti-inflammatory drugs (NSAIDs)
concomitantly with an anti-NGF monoclonal antibody.
Dogs have no reported equivalent of human rapidly progressive osteoarthritis.
No other laboratory studies on the safety of concomitant administration of this
veterinary medicinal product with other veterinary medicinal products have been
conducted. No interactions were observed in field studies where this veterinary
medicinal product was administered concomitantly with veterinary medicinal products
containing parasiticides, antimicrobials, topical antiseptics with or without
corticosteroids, antihistamines and vaccines.
If a vaccine(s) is to be administered at the same time as treatment with this veterinary
medicinal product, the vaccine(s) should be administered at a different site to that of
the veterinary medicinal products administration, to reduce any potential impact on
immunogenicity of the vaccine.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Store in the original package.
Protect from light.
Aseptically withdraw 0.1 ml/kg from a single 5 mg/ml vial and administer
subcutaneously.
For dogs between 5 and 60 kg administer the entire content of the vial (1 ml)
according to the table below:
Librela strength (mg) to be administeredBodyweight (kg) of dog51015 20 30 5.0-10.01 vial10.1-20.01 vial20.1-30.01 vial30.1-40.01 vial40.1-60.01 vial60.1-80.02 vials80.1-100.01 vial 1 vial100.1-120.002 vials

Revised: January 2026
AN: 02281/2025
For dogs above 60 kg, the contents of more than one vial are required to administer
a single dose. In those cases, withdraw the content from each required vial into the
same syringe and administer as a single subcutaneous injection (2 ml).
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No adverse reactions, except mild reactions at the injection site, were observed in a
laboratory overdose study when the veterinary medicinal product was administered
for 7 consecutive monthly doses at 10 times the maximum recommended dose.
In case of adverse clinical signs after an overdose the dog should be treated
symptomatically.
4.11 Withdrawal period(s)
Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.